At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 65 enrolled
Drug / intervention
nab-paclitaxel +1 moredrug
Likely dose
nab-paclitaxel 125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Nab-Paclitaxel and Ramucirumab for the Second-line Treatment of Patients With Metastatic Gastroesophageal Cancer
In Brief
A Phase 2 clinical trial evaluating nab-paclitaxel and ramucirumab for Gastroesophageal Cancer. Completed, enrolled 65 participants across 11 sites.
Detailed Summary
The purpose of this study is to determine whether nab-Paclitaxel (Abraxane®) and ramucirumab (Cyramza®) are effective when used in combination for treating patients with metastatic gastroesophageal cancer who have either progressed or not responded to prior therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroesophageal Cancer
CountriesUnited States
CollaboratorsCelgene
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartMay 2015
Primary CompletionMay 2021
TodayJul 2026
First PostedDec 17, 2014
Enrollment StartMay 5, 2015
Primary CompletionMay 21, 2021
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 11.5 years ago
Interventions
nab-paclitaxeldrug
nab-paclitaxel 125 mg/m\^2 IV
ramucirumabbiological
Ramucirumab 8 mg/kg IV